Skip to main navigation
Skip to search
Skip to main content
WashU Medicine Research Profiles Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
The cancer immunotherapy biomarker testing landscape
Eric E. Walk
, Sophia L. Yohe
, Amy Beckman
, Andrew Schade
, Mary M. Zutter
,
John Pfeifer
, Anna B. Berry
Division of Anatomic and Molecular Pathology (AMP)
Institute of Clinical and Translational Sciences (ICTS)
Siteman Cancer Center
Research output
:
Contribution to journal
›
Article
›
peer-review
79
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The cancer immunotherapy biomarker testing landscape'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Cancer Immunotherapy
100%
Biomarker Testing
100%
Immunological Biomarkers
100%
Immune Response
20%
Pathologist
20%
Microsatellite Instability-high (MSI-H)
20%
Programmed Death-ligand 1 (PD-L1)
20%
Mismatch Repair
20%
Clinical Response
10%
Tumor Subtype
10%
Clinical Data
10%
U.S. Food
10%
Patient Characteristics
10%
Microbiome
10%
Cancer Patients
10%
Response Predictors
10%
Patient Response
10%
Tumor Characteristics
10%
Tumor mutational Burden
10%
Polymerase
10%
Translational Studies
10%
Transcriptional Signature
10%
Novel Biomarkers
10%
Clinical Trial Data
10%
Predictive Biomarker
10%
Testing Method
10%
Tumor-infiltrating Lymphocytes
10%
Clinical Testing
10%
Cancer Neoantigens
10%
Current Field
10%
Substantial Clinical Benefit
10%
Companion Diagnostics
10%
Scientific Background
10%
Immunotherapy Resistance
10%
Late-stage Cancer
10%
Resistance Biomarkers
10%
Data Methodology
10%
Medicine and Dentistry
Biological Marker
100%
Cancer Immunotherapy
100%
Neoplasm
20%
Immune Response
20%
Pathologist
20%
Programmed Death 1 Ligand 1
20%
Microsatellite Instability
20%
DNA Mismatch Repair
20%
Malignant Neoplasm
10%
Clinical Trial
10%
Patient Characteristics
10%
Cancer Staging
10%
Microbiome
10%
Polymerase
10%
Tumor Infiltrating Lymphocyte
10%
Tumor Mutational Burden
10%
Immunology and Microbiology
Cancer Immunotherapy
100%
Immune Response
20%
Microsatellite Instability
20%
Programmed Death 1 Ligand 1
20%
Mismatch Repair
20%
Cancer Staging
10%
Neoantigen
10%
Tumor-Infiltrating Lymphocytes
10%
Microbiome
10%
Tumor Mutational Burden
10%
Material Science
Tumor
100%
Lymphocyte
25%